Publications

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Reply to T. Magnes et al.

10-07-2016

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Liquid chromatography-tandem mass spectrometric assay for ponatinib and N-desmethyl ponatinib in mouse plasma.

15-06-2016

Journal of pharmaceutical and biomedical analysis

Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.

05-06-2016

Neuro-oncology

EpCAM-based flow cytometry in cerebrospinal fluid greatly improves diagnostic accuracy of leptomeningeal metastases from epithelial tumors.

01-06-2016

Cancer chemotherapy and pharmacology

A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine.

01-06-2016

Investigational new drugs

Metabolite profiling of the multiple tyrosine kinase inhibitor lenvatinib: a cross-species comparison.

01-06-2016

Journal of pharmacokinetics and pharmacodynamics

The performance of model-based versus rule-based phase I clinical trials in oncology : A quantitative comparison of the performance of model-based versus rule-based phase I trials with molecularly targeted anticancer drugs over the last 2 years.

01-06-2016

European journal of clinical pharmacology

Pharmacodynamic modeling of adverse effects of anti-cancer drug treatment.

01-06-2016

International journal of cancer

Rs895819 in MIR27A improves the predictive value of DPYD variants to identify patients at risk of severe fluoropyrimidine-associated toxicity.

01-06-2016

Drug metabolism reviews

Regulatory aspects of human radiolabeled mass balance studies in oncology: concise review.

01-05-2016

British journal of clinical pharmacology

Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.

01-05-2016

Cancer

Bevacizumab combined with docetaxel, oxaliplatin, and capecitabine, followed by maintenance with capecitabine and bevacizumab, as first-line treatment of patients with advanced HER2-negative gastric cancer: A multicenter phase 2 study.

01-05-2016

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Corrigendum to "Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine" [J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 893-894 (2012) 92-100].

01-05-2016

Antimicrobial agents and chemotherapy

Validation and Clinical Evaluation of a Novel Method To Measure Miltefosine in Leishmaniasis Patients Using Dried Blood Spot Sample Collection.

01-04-2016

Journal of neurology

Strategies to target drugs to gliomas and CNS metastases of solid tumors.

01-03-2016

The AAPS journal

Development of a Tumour Growth Inhibition Model to Elucidate the Effects of Ritonavir on Intratumoural Metabolism and Anti-tumour Effect of Docetaxel in a Mouse Model for Hereditary Breast Cancer.

01-03-2016

Lung cancer (Amsterdam, Netherlands)

Crizotinib-induced fatal fulminant liver failure.

01-03-2016

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Liquid chromatography-tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquid-liquid extraction.

15-02-2016

Investigational new drugs

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.

01-02-2016

European journal of cancer (Oxford, England : 1990)

Renal function, body surface area, and age are associated with risk of early-onset fluoropyrimidine-associated toxicity in patients treated with capecitabine-based anticancer regimens in daily clinical care.

01-02-2016

International journal of cancer

Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model.

01-02-2016

Journal of pharmaceutical and biomedical analysis

Liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies.

25-01-2016

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis.

20-01-2016

Cancers

Pharmacokinetics of Selected Anticancer Drugs in Elderly Cancer Patients: Focus on Breast Cancer.

02-01-2016

International journal of cancer

Increased risk of severe fluoropyrimidine-associated toxicity in patients carrying a G to C substitution in the first 28-bp tandem repeat of the thymidylate synthase 2R allele.

01-01-2016

Bioanalysis

Development and clinical validation of an LC-MS/MS method for the quantification of pazopanib in DBS.

15-12-2015

Cancer treatment reviews

The use of combinations of monoclonal antibodies in clinical oncology.

01-12-2015

Cancer chemotherapy and pharmacology

Phase 1a/1b and pharmacogenetic study of docetaxel, oxaliplatin and capecitabine in patients with advanced cancer of the stomach or the gastroesophageal junction.

01-12-2015

Investigational new drugs

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer.

01-12-2015

Therapeutic drug monitoring

Dried Blood Spot Self-Sampling at Home for the Individualization of Tamoxifen Treatment: A Feasibility Study.

01-12-2015

Pharmacological research

Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).

01-12-2015

The Lancet. Oncology

Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data.

01-12-2015

Current colorectal cancer reports

Treatment Individualization in Colorectal Cancer.

01-12-2015

International journal of cancer

ABCB1 and ABCG2 restrict the brain penetration of a panel of novel EZH2-Inhibitors.

15-10-2015

Molecular pharmaceutics

P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice.

05-10-2015

Investigational new drugs

P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.

01-10-2015

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Validation of high-performance liquid chromatography-tandem mass spectrometry assays quantifying omacetaxine mepesuccinate and its 4'‑des-methyl and cephalotaxine metabolites in human plasma and urine.

01-10-2015

Veterinary and comparative oncology

Determination of platinum surface contamination in veterinary and human oncology centres using inductively coupled plasma mass spectrometry.

01-09-2015

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences

Quantification of miltefosine in peripheral blood mononuclear cells by high-performance liquid chromatography-tandem mass spectrometry.

15-08-2015

Clinical breast cancer

Tailored Tamoxifen Treatment for Breast Cancer Patients: A Perspective.

01-08-2015

British journal of clinical pharmacology

Pharmacodynamics and pharmacokinetics of oral topotecan in patients with advanced solid tumours and impaired renal function.

01-08-2015

Clinical pharmacokinetics

Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.

01-08-2015

British journal of cancer

Long-term safety and anti-tumour activity of olaparib monotherapy after combination with carboplatin and paclitaxel in patients with advanced breast, ovarian or fallopian tube cancer.

28-07-2015

CPT: pharmacometrics & systems pharmacology

Integrated Simulation Framework for Toxicity, Dose Intensity, Disease Progression, and Cost Effectiveness for Castration-Resistant Prostate Cancer Treatment With Eribulin.

01-07-2015

Pharmaceutical research

Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).

01-07-2015

Clinical lung cancer

Concentrations of Erlotinib in Tumor Tissue and Plasma in Non-Small-Cell Lung Cancer Patients After Neoadjuvant Therapy.

01-07-2015

CPT: pharmacometrics & systems pharmacology

Disease Progression/Clinical Outcome Model for Castration-Resistant Prostate Cancer in Patients Treated With Eribulin.

01-07-2015

Journal of pharmaceutical and biomedical analysis

Development of an LC-MS/MS assay for the quantitative determination of the intracellular 5-fluorouracil nucleotides responsible for the anticancer effect of 5-fluorouracil.

10-06-2015

Veterinary and comparative oncology

Inductively coupled plasma mass-spectrometric determination of platinum in excretion products of client-owned pet dogs.

01-06-2015

Cancer treatment reviews

Variability in bioavailability of small molecular tyrosine kinase inhibitors.

01-05-2015